What Versatis Treats: Main Uses and Benefits

Versatis is commonly used for managing localized, persistent nerve pain in adults, specifically the chronic condition known as post-herpetic neuralgia (PHN), which follows a healed shingles infection. This topical treatment is commonly used to help manage the highly distressing cluster of symptoms characteristic of PHN, which includes continuous burning, shooting, or stabbing sensations, which are often challenging symptoms to manage.

Easing Hypersensitivity and Allodynia

This therapy is applied to address skin hypersensitivity. The medication may assist with managing symptoms like allodynia (pain caused by light touch or clothing), which are symptoms that interfere with daily functioning. By providing focused relief, the patch contributes to easing the overall symptom load during symptomatic periods and helps maintain a sense of stability when symptoms are more noticeable. Used in chronic pain management, this approach provides support that helps ease the overall symptom burden, assisting with maintaining functional stability and managing symptoms that interfere with rest.

---

Quick Fact: Relief for Localized Neuropathic Pain The plaster is commonly used to help address symptoms related to peripheral nerve dysfunction, which typically manifests as focused, persistent discomfort in a defined area of the skin.

Eligibility Scope

Versatis is officially indicated for use exclusively in adult patients (18 years and older), including the elderly. Use is not recommended for the pediatric population (under 18 years of age) because the safety and effectiveness of the patch have not been established in this group.

Absolute Contraindications

The medicine is contraindicated and must not be used in patients with a known history of hypersensitivity to lidocaine or to other amide-type local anaesthetics (e.g., bupivacaine, etidocaine). Furthermore, the plaster must not be applied to inflamed or injured skin, active herpes zoster lesions, open wounds, or atopic dermatitis, and should only be applied to intact, dry skin.

Conditional and Restricted Use

The patch must be used with caution in patients diagnosed with severe hepatic impairment, severe renal impairment, or severe cardiac impairment. This is due to the potential for delayed systemic clearance, which may lead to higher lidocaine concentrations. During pregnancy, Versatis should not be used unless clearly necessary; for lactation, an effect on the infant is unlikely due to low systemic absorption, but data is limited.

Connection to the Overall Eligibility Profile

Official regulatory documents define eligibility primarily by age (approved for adults only), immune status (contraindicated with known allergies), and pre-existing medical conditions (restricted use with severe organ impairment). These constraints establish that the medicine is reserved for the approved adult population, ensuring the patient does not have an absolute contraindication or an organ impairment that could lead to increased systemic exposure.

Interactions with other medicines and products

Given the low systemic absorption of lidocaine from the Versatis 5% patch, the likelihood of clinically relevant pharmacokinetic drug interactions is low when the patch is used as directed. The official regulatory profile primarily focuses on precautions against additive effects and factors that can increase systemic exposure.

Pharmacodynamic Interactions

Caution is advised when Versatis is used concurrently with Class I antiarrhythmic medicinal products (such as mexiletine or tocainide). Due to the systemic absorption of lidocaine, these combinations may result in additive effects on the heart and central nervous system. Similarly, co-administration with other local anaesthetic agents requires caution due to the risk of combined systemic toxicity.

Factors Influencing Systemic Exposure

Conditions that increase the absorption of lidocaine must be avoided to prevent elevated plasma concentrations and potential interactions:

• External Heat: Applying heat sources (like heating pads) directly over the patch may accelerate lidocaine absorption.
• Skin Condition: Use on inflamed, injured, or non-intact skin (outside of the application area) can increase systemic absorption.

Population-Specific Considerations

Caution is advised for patients with severe hepatic impairment or severe renal impairment. In these populations, the reduced ability to clear lidocaine and its metabolites may lead to sustained, increased systemic concentrations, elevating the potential for interactions.

Versatis is a topical delivery system for the amide-type local anesthetic, lidocaine. Following permeation through the stratum corneum, lidocaine selectively accumulates in the local subcutaneous and dermal tissues, specifically engaging peripheral nerve fibers and their terminals.

Its primary biological target is the voltage-gated sodium channel (VGSC), predominantly isoforms such as Nav1.7 and Nav1.8, which are expressed on nociceptive primary afferent neurons. Lidocaine acts as a non-competitive inhibitor of the VGSC, binding reversibly to a site within the channel's inner pore while it is in the open or inactivated conformational state.

This molecular interaction stabilizes the channel in an inactivated, non-conducting conformation. The downstream intracellular consequence is a blockade of the transient influx of sodium ions required for cell membrane depolarization. This prevents the generation and propagation of action potentials along the afferent nerve fibers, resulting in a systemic-level physiological consequence of localized afferent impulse suppression without a complete motor or sensory block.

Versatis is an adhesive, medicated cutaneous plaster designed for topical application directly to the skin. The official instructions define a specific daily cycle and dose limits that must be followed strictly for its proper use.

Official Dosing and Cyclic Schedule

Feature	Guideline
Route of Administration	Topical (Dermal)
Maximum Dose	Not more than three plasters may be worn simultaneously.
Dosing Cycle	Applied once daily for a maximum of 12 consecutive hours.
Patch-Free Interval	A subsequent plaster-free period of at least 12 hours is mandatory.

Administration Requirements

The plaster should only be applied to intact, non-irritated skin that is clean and dry. For patients with hair in the affected area, the hairs must be cut off with scissors; they should not be shaved. If necessary to cover the painful area, the plaster may be cut into smaller pieces before the release liner is removed. The product is intended for use in adults and elderly patients, with no specific dosage adjustment required for those with mild to moderate renal or hepatic impairment. Safety and efficacy have not been established in children below 18 years of age.

Course Duration Protocol

Treatment outcome should be formally re-evaluated after 2 to 4 weeks to determine the benefit. For continued use, the regimen should be regularly reassessed to consider reducing the number of plasters needed or extending the 12-hour patch-free interval.

Versatis: Recent Clinical Evidence

Indication and Efficacy Studies

The 5% lidocaine medicated plaster (Versatis) is licensed for the symptomatic relief of neuropathic pain associated with previous herpes zoster infection, a condition known as post-herpetic neuralgia (PHN). Randomized controlled trials (RCTs) investigating the plaster's effect versus a placebo or vehicle plaster demonstrated an association with pain reduction in some participants with PHN. The onset of observed pain relief may vary, sometimes requiring two to four weeks for the full effect to be assessed.

Evidence from early studies was noted by regulatory reviewers to involve enriched populations, meaning participants were only included if they had already responded to the treatment during a preliminary phase. This methodological approach has contributed to ongoing discussion regarding the strength and generalizability of the initial efficacy evidence.

Safety Profile and Tolerability

Studies generally report that the lidocaine plaster is well-tolerated, particularly when compared to certain systemic (oral) medications often prescribed for PHN. The low incidence of systemic adverse effects is attributed to the minimal systemic absorption of lidocaine from the topical patch (estimated to be around 3%).

Adverse events reported in clinical trials were most commonly mild to moderate administration site reactions, such as rash, itching, burning, and redness. Given the common occurrence of PHN in older adults, the localized application and generally favorable tolerability profile are factors frequently discussed in the clinical literature, although guidelines vary on its placement as a first- or second-line treatment option.

Key Studies & References

1. The kinetics of lidocaine absorption following application of the 5% lidocaine patch to intact skin in normal volunteers

Common questions about Versatis (FAQ)

Q: What should I do if the application site becomes severely itchy or blisters?

A: Local skin reactions like redness, itching, and rash are frequently reported side effects. If a severe reaction occurs, such as blistering, skin laceration, or hives (urticaria), the official safety information advises caution or discontinuation of the patch. Observing the signs of severe irritation is important for appropriate response.

Q: Can I shower, bathe, or swim while wearing the Versatis patch?

A: Contact with water should be avoided while the patch is being worn during the 12-hour application period. The mandatory 12-hour patch-free interval is the period during which bathing, showering, or swimming is typically permitted according to official guidance.

Q: Can Versatis cause systemic side effects, like those that affect the heart or nerves?

A: Systemic side effects following appropriate use are considered unlikely because the systemic concentration of the active ingredient (lidocaine) is very low. However, common systemic effects observed in clinical trials included headache and dizziness. Official documents also advise caution for patients with cardiac conduction abnormalities due to the potential for additive effects from absorbed lidocaine.

Q: Is Versatis safe to use if I am also taking other prescribed pain medications?

A: Due to the low systemic absorption when the patch is used as directed, the risk of clinically relevant drug interactions is considered low. Caution is specifically advised in regulatory documents when used alongside other local anaesthetics or with Class I antiarrhythmic medications. These combinations could lead to additive toxic effects on the heart and nervous system.

Q: Can Versatis be safely used by people with severe kidney problems?

A: Official product information states that the patch should be used with caution in patients who have severe renal (kidney) impairment. This is because a reduced ability to clear the medicine and its byproducts may lead to sustained, increased concentrations of the drug in the bloodstream.

Q: Is Versatis safe for use by patients who have liver conditions?

A: Regulatory documents advise that the patch should be used with caution in patients who have severe hepatic (liver) impairment. This is because a severely impaired liver may reduce its ability to break down the active ingredient, potentially increasing the risk of elevated blood concentrations.

Q: Does applying the patch for more than 12 hours increase the risk of side effects?

A: Yes. The official dosing cycle requires a minimum 12-hour patch-free period every day. Applying the patch for longer than the recommended 12-hour wearing time can increase the systemic absorption of the active ingredient, which could potentially lead to systemic adverse effects.

Q: Are there specific symptoms that indicate the lidocaine is being absorbed too much?

A: Signs of excessive absorption leading to systemic toxicity can include symptoms such as light-headedness, ringing in the ears (tinnitus), or numbness and tingling around the mouth and tongue. These symptoms are expected at blood concentrations higher than those typically achieved when the patch is used as directed.

Q: Does Versatis affect a person's ability to drive or operate machinery?

A: Official documentation states that studies on the effects on the ability to drive or use machines have not been performed. However, an effect is considered unlikely because the systemic absorption of the active ingredient is minimal when the patch is used correctly.

Q: Is it common to have skin redness or irritation where the patch was applied?

A: Yes, it is common. Application site reactions such as redness (erythema), itching (pruritus), and rash are reported as very common adverse drug reactions in official safety documentation. These reactions are localized to the application area and are generally mild and temporary.

Q: Is Versatis the same as an over-the-counter lidocaine patch?

A: No. Versatis is a prescription-only product that contains 5%, w/w lidocaine. It is specifically licensed and indicated for the treatment of pain associated with post-herpetic neuralgia (PHN). Over-the-counter lidocaine patches typically contain a lower strength, such as 4%, and are indicated for the temporary relief of minor aches and pains.

Q: What is the difference between Versatis and other pain patches like prescription NSAID patches?

A: Versatis is classified as a local anesthetic, which means it works by stabilizing nerve cell membranes to block pain impulses directly at the application site. Other prescription pain patches, such as those containing NSAIDs, work through a different pharmacological action focused on reducing inflammation.

Q: What is the difference between the 5% lidocaine patch and the 4% lidocaine patch mentioned in forums?

A: The officially authorized medicinal product is the 5% lidocaine medicated patch, which requires a prescription and is licensed for specific neuropathic pain. The 4% patch is typically an over-the-counter product used for minor pain and has a different intended use and strength.

Q: Are there any long-term side effects associated with using Versatis for months or years?

A: Official protocol defines that the treatment course must be formally reassessed at regular intervals to determine continued necessity. Clinical evidence of use over periods of up to 12 months suggests the patch is generally well-tolerated. The most common adverse events remain the localized skin reactions at the application site.

Q: How quickly should I expect to feel pain relief after applying the patch?

A: Clinical trials have shown that the patch can begin to provide statistically significant pain reduction starting from about 4 hours after application compared to a non-medicated patch. However, official documents indicate that the full therapeutic effect for some patients may require 2 to 4 weeks of consistent use to properly assess.

Q: Does the pain relief from Versatis continue even during the 12-hour patch-free period?

A: The official product information defines the required 12-hour patch-free interval but does not detail the pharmacological persistence of the relief during this period. The patch must be removed after 12 hours so that the mandatory patch-free period is maintained.

Q: Can I use lotions or creams on my skin during the time when the patch is not being worn?

A: Yes. According to the official patient information, it is acceptable to use creams and lotions on the affected skin area during the 12-hour period when the patch is not being worn. The skin must be clean and dry again before the next patch is applied.

Q: Is there any evidence that Versatis is addictive?

A: The active ingredient, lidocaine, is a local anaesthetic and is not classified as an opioid or narcotic substance. Its mechanism of action is local, non-systemic, and does not engage the central nervous system pathways typically associated with dependency.

Q: Is Versatis treatment reviewed regularly by a doctor?

A: The official treatment protocol indicates that the treatment outcome must be formally re-evaluated after 2 to 4 weeks to determine the clinical benefit. For continued use, treatment must be reassessed at regular intervals to consider reducing the dosage or extending the patch-free period.

Q: Does Versatis have an expiry date, and can the patch dry out if stored incorrectly?

A: The patch must be kept in its original sachet to protect it from light and moisture. The official instructions warn that the patch contains water and can dry out. Once the sachet is opened, it must be kept tightly closed, and the contents must be used within 14 days.

Q: Can I use an external heat source, like a heating pad, over the patch?

A: The placement of external heat sources, such as heating pads or electric blankets, directly over the patch is not recommended. Official documentation indicates that external heat may accelerate the absorption of the active ingredient and increase its blood concentration.

Q: What happens if I forget to put on a new patch after the 12-hour patch-free interval?

A: If it is almost time for the next scheduled application, the missed application should be skipped, and the next patch should be applied at the regular time. Otherwise, official information states that a new patch should be applied as soon as the lapse is remembered, and then the normal 12-hour application schedule should be resumed.

Q: Can Versatis be used for pain other than post-herpetic neuralgia?

A: The patch is officially licensed and indicated exclusively for the symptomatic relief of neuropathic pain associated with previous herpes zoster infection. This condition is also known as post-herpetic neuralgia (PHN).

Q: Is the patch only for pain related to shingles, or can it be used for other types of nerve pain?

A: According to official regulatory documentation, the patch is only licensed and indicated for the symptomatic relief of neuropathic pain that is associated with previous herpes zoster infection (shingles). This is the specific condition known as post-herpetic neuralgia (PHN).

How to Store and Dispose of Versatis

Versatis (lidocaine medicated plaster) must be stored and handled according to specific regulatory requirements to maintain product quality and safety.

Storage Requirements

The plaster must be stored at a temperature below 25 C and must not be refrigerated or frozen. The product should be kept in its original sachet to protect it from light and moisture. Once the sachet is opened, it must be kept tightly closed, and the contents must be used within 14 days.

Disposal Instructions

All used and unused plasters must be kept out of the sight and reach of children and pets. After use, the plaster should be folded in half, with the sticky sides together, before being discarded. Medicines must not be disposed of via wastewater or regular household waste; unused product should be returned to a pharmacist or disposed of according to local environmental regulations.